Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes an...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Meng Yang, Jingwen Zhang, Dongqun Wei, Tianyi Yu, Zeyu Chen, Xin Liu, Haitao Zhu
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	BMC 2024-02-01
Sraith:	BMC Cancer
Ábhair:	Immunotherapy Urothelial carcinoma Inflammatory markers Tislelizumab Survival
Rochtain ar líne:	https://doi.org/10.1186/s12885-024-11969-5
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!